Health Condition 1: G431- Migraine with aura
Conditions
Interventions
Intervention1: Scutellaria lateriflora (Homeopathic Medicine)
: Homeopathic medicine Scutellaria lateriflora in various potencies (30C, 200C, 1M, and higher as required on individual basis), administ
Sponsors
Dr M P K Homeopathic Medical College Hospital And Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either gender aged between 18to50 years. Diagnosed cases of Migraine as per ICD10 G43 criteria. Patients experiencing recurrent migraine attacks for at least least twice/month. Patients willing to give informed consent and comply with study procedures.
Exclusion criteria
Exclusion criteria: 1 Patients currently on Conventional migraine prophylactic treatment or unwilling to stop such treatments. 2 Patients with secondary headaches (example due to sinusitis hypertension tumours). 3 Patients with Psychiatric disorders that may interfere with evaluation. 4 Patients with chronic systemic illnesses (e.g., uncontrolled diabetes cardiac diseases and epilepsy). 5 Pregnant or lactating women will be excluded from the study. 6 Patients with Known hypersensitivity or intolerance to any constituent of the selected homeopathic remedies. 7 Patients participating in any other clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in frequency, duration, and intensity of migraine attacks as measured by Migraine Disability Assessment Score (MIDAS). Improvement in clinical symptoms of migraine assessed by Symptom Assessment Scale. PRE AND POST TREATMENTTimepoint: Baseline (Day 0, before intervention). During treatment (monthly follow-up at 4, 8 weeks). At the end of study (12 weeks / 3 months). | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Symptom Assessment Scale score (frequency, intensity, duration of headache, associated symptoms like nausea, photophobia, phonophobia). Change in Quality of Life parameters (sleep, work efficiency, daily activity). Reduction in use of rescue medication/analgesics (if applicable). Recording of any adverse events or side effects of the intervention.Timepoint: Baseline (Day 0, before intervention). During treatment (monthly follow-up at 4, 8 weeks). At the end of study (12 weeks / 3 months). | — |
Countries
India
Contacts
Public ContactDr Priyanka Saini
Dr M P K Homeopathic Medical College Hospital and Research centre
Outcome results
None listed